WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”). Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky who, along with Dr. Kent Walker, performed one ...

核心观点 - 公司报告期内净资产值小幅下降但维持稳定 支付股息并完成多项新投资和追加投资 投资组合集中在科技和医疗健康领域 [2][3][4][5] - 公司通过取消股份溢价账户增加可分配储备 为未来股息支付和股份回购提供资金支持 [9][10] 财务表现 - 截至2025年6月30日未经审计净资产值为2.773亿英镑或每股115.72便士 较2025年3月31日下降0.50便士每股（0.4%）[3] - 支付2026财年首次股息每股2.91便士 除息后净资产值调整为每股112.81便士 [3] - 2025年8月29日通过股息再投资计划发行979,850股普通股 发行价格为每股113.31便士 总投资额111万英镑 [11] 投资活动 - 新增投资总额565.5万英镑 包括Total Access Health（338.5万英镑）Labrys Group Holdings（200.3万英镑）和Revgentic（26.7万英镑）[4] - 追加投资总额507.1万英镑 涉及Get Least（124.2万英镑）Gravitee TopCo（121.4万英镑）Phasecraft（101.2万英镑）等8家企业 [4] - 前十大持仓占净资产比重最高为Quantexa（5406.5万英镑 占19.5%）其次为Oviva（1723.9万英镑 占6.2%）和Proveca（1483.7万英镑 占5.3%）[5][6] 公司治理 - 报告期内未进行股份回购 因处于闭锁期 [7] - 董事会政策允许在市场条件允许时以净资产值约5%折让进行股份回购 [8] - 2024年12月11日股东大会授权取消股份溢价账户 2025年5月13日获法院批准 增加1.955亿英镑可分配储备 [9][10]

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable MarketLONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product in the Obagi® saypha® collection under t ...

Company Announcement no. 05-2025 Copenhagen, 10th September 2025 Swiss Properties Invest publishes half yearly report after another positive semester The first half year of 2025 has continued to be good for business in Swiss Properties Invest. H1 2025 Financial highlights The group revenue reached DKK 18.7m compared to DKK 16.8m for H1 2024.The group operating profit reached DKK 11.8m compared to DKK 11.4m for H1 2024.Profit after tax for the group reached DKK 7.8m compared to DKK 6.0m during H1 2024. In ...

BEIJING, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Bank of China Beijing Marathon 2025 officially opened for global registration at 10:00 AM on September 10. Global participants can register on the Beijing Marathon website (https://en.beijing-marathon.com/) or the Bank of China website (https://www.boc.cn/en/). A Media Snippet accompanying this announcement is available by clicking on this link. The race will begin at 7:30 AM on November 2, with an expected 32,000 runners taking to the course for a golden au ...

TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX:DPM) (“DPM”) today reported high-grade copper-gold-silver intercepts from its ongoing Serbian exploration program, including the Dumitru Potok prospect. Results included an intercept of 131.6 metres grading 3.93% CuEq, comprised of 1.53% Cu, 2.41 g/t Au and 12 g/t Ag from 1,126 metres and 76 metres at 2.47% CuEq, comprised of 1.01% Cu, 1.43 g/t Au and 10.37 g/t Ag from 1,277 metres downhole at hole DPDD032. This represents one of t ...

Hong Kong, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (Nasdaq: CRE) (“Cre8” or the “Company”), a Hong Kong-based integrated financial printing service provider, announced today that it is actively exploring strategic alliances with financial printing and compliance solution providers in Japan. These partnerships are intended to strengthen support for cross-border IPOs and dual listings, while enhancing the delivery of integrated solutions for multinational issuers. By leveraging local expert ...

核心观点 - BXCL501在家庭环境中对双相情感障碍或精神分裂症相关躁动治疗显示出持续疗效和一致性益处 计划于2026年第一季度提交补充新药申请(sNDA)以扩大IGALMI®在门诊环境中的使用范围 [1][2][10] 临床试验设计 - SERENITY At-Home试验为关键性3期双盲安慰剂对照12周临床试验 旨在评估120 mcg剂量BXCL501在家庭环境中治疗躁动的安全性 [3][16] - 试验纳入246名随机患者 在215名患者中收集了2,628次躁动发作数据 其中2,437次发作在208名患者中得到治疗 [4] - 患者组成比例为45%双相情感障碍和55%精神分裂症 所有患者均能成功自行服用薄膜制剂 [4] 疗效结果 - 在2,433次治疗发作中 BXCL501在2小时时显示mCGI-S评分较基线平均降低显著优于安慰剂(p<0.05) [1][6] - 总体完全缓解率BXCL501组为50% 显著高于安慰剂组的33%(p<0.0001) [7] - 严重躁动发作完全缓解率BXCL501组为61% 显著高于安慰剂组的18%(p<0.0001) [7] - 中度躁动发作完全缓解率BXCL501组为43% 显著高于安慰剂组的34%(p<0.0005) [7] - 轻度躁动发作完全缓解率BXCL501组为60% 显著高于安慰剂组的40%(p<0.0001) [7] 持续疗效表现 - 首次12次给药后mCGI-S评分平均降低1.2 13次或更多给药后平均降低1.4 显示重复给药的持续益处 [8] - 在12周试验期间 第1-4周、5-8周和9-12周接受BXCL501治疗的躁动发作均显示mCGI-S评分平均降低1.3 [9] 市场机会与未满足需求 - 公司估计总可寻址市场为每年5700-7700万次躁动发作 显著高于先前估计的2300万次 [12] - 目前家庭环境中没有FDA批准的急性躁动治疗疗法 存在重大未满足医疗需求 [3][11] - 市场调查显示患者平均每月经历3-4次躁动发作 其中大部分为中度或重度 [12] 监管进展与计划 - 基于大量证据和FDA积极反馈 公司计划2026年第一季度提交sNDA以扩大IGALMI®在门诊环境中的使用 [1][2] - BXCL501于2018年12月获得快速通道资格认定 用于治疗双相情感障碍或精神分裂症相关躁动 [11] - 试验设计和方案已与FDA事先达成一致 [10] 产品背景 - IGALMI®(地塞米托咪定舌下薄膜)目前获FDA批准用于医疗监督环境下治疗双相情感障碍或精神分裂症相关躁动 [10][18] - BXCL501是一种研究性口服溶解薄膜制剂 为选择性α2肾上腺素能受体激动剂 [18] - 产品提供120 mcg和180 mcg两种剂量规格 [10]

OMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE 10 SEPTEMBER 2025 AT 1.25 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE S&P Global Ratings affirmed Oma Savings Bank Plc's credit rating and changed outlook to negative On 10.9.2025 June 2025, S&P Global Ratings (S&P) has affirmed that the short-term and long-term issuer credit ratings of Oma Savings Bank Plc (OmaSp or the Company) remain unchanged and are BBB/A-2. At the same time, S&P has changed OmaSp's outlook from stable to nega ...

披露主体信息 - Man Group PLC作为披露方于2025年9月9日持有Spectris plc头寸[1] - 本次披露涉及标的公司为Spectris plc的5便士普通股[1][3] 持仓详情 - 通过现金结算衍生品持有1,178,432股Spectris普通股 占已发行股本1.19%[3] - 总持仓均为多头衍生品头寸 无实物股票持仓及空头头寸[3] - 未持有股票结算衍生品或认购权证[3][5] 交易活动 - 通过股权互换产品进行多笔增减仓操作 交易价格区间为40.9147-40.9400英镑[8] - 增持操作共3笔 合计3,795股 最高价40.9244英镑[8] - 减持操作共4笔 合计3,342股 最低价40.9109英镑[8] - 未进行实物股票交易及其他类型衍生品交易[7][9][10][11] 附加信息 - 披露日期为2025年9月10日 联系人为Molly Childs[14] - 不存在与要约相关的补偿安排或投票权协议[12][13] - 未附加开放式头寸补充表格[14]